AstraZeneca Plc.
(NASDAQ:AZN) said its Phase 3 I CAN trial evaluating Ultomiris (ravulizumab) in adults with immunoglobulin A nephropathy (IgAN) at risk of disease progression met a prespecified interim endpoint.
The study showed a statistically significant and clinically meaningful reduction in proteinuria compared with placebo at week 34.
AstraZeneca's Ultomiris Cuts Proteinuria According to the interim analysis, patients treated with Ultomiris achieved a 46.6% reduction in 24-hour urine protein creatinine ratio (UPCR) from baseline, compared with a 5.6% reduction in the placebo group.
The placebo-adjusted treatment effect was 43.4%, with the result reaching statistical significance (p<0.0001).
